SI-BONE: Fairly Valued Medtech After Opening Day Jump
(WorldNews Health)

SI-BONE (SIBN) is a minimally invasive medtech company, with narrowing losses and reasonably modest sales growth. The company has gone public in an IPO which was well received by the market. SIBN is an interesting play and is still a relatively small player in a huge potential market. Valuations remain reasonable at nearly 8 times annualised sales, as revenue growth comes in around 15% and losses are coming down. On the other hand, idiosyncratic risks are very high, which include the reliance on a single product, losses, and potentially superior competitive offerings. Considering shares to be reasonably valued, I have a neutral stance at this point, looking for further clues about growth and...